Cargando…
Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis
Entecavir (ETV) is a first‐line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV‐resistant (ETVr) HBV DNA resulted from substitutions in the HBV reverse transcriptase (RT) at positions...
Autores principales: | Rose, Ronald E., Hernandez, Dennis, Falk, Paul J., Ericson, Karen, Zhou, Nannan, Thiry, Alexandra, McPhee, Fiona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128232/ https://www.ncbi.nlm.nih.gov/pubmed/30202825 http://dx.doi.org/10.1002/hep4.1231 |
Ejemplares similares
-
Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions
por: Lai, Ming-Tain, et al.
Publicado: (2016) -
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir
por: Friborg, Jacques, et al.
Publicado: (2014) -
50th anniversary of the discovery of reverse transcriptase
por: Coffin, John M.
Publicado: (2021) -
Antiviral Efficacy of Entecavir versus Entecavir plus Adefovir for Hepatitis B Virus rtA181V/T Mutants Alone
por: Oh, Myung Jin, et al.
Publicado: (2016) -
Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants
por: Li, Ping, et al.
Publicado: (2017)